Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Patients with newly diagnosed advanced ovarian cancer were randomly assigned to receive daily niraparib, a PARP inhibitor, or placebo as maintenance therapy after having had a response to platinum-based chemotherapy. Progression-free survival was significantly longer in the niraparib group than in t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-12, Vol.381 (25), p.2391-2402
Hauptverfasser:	González-Martín, Antonio, Pothuri, Bhavana, Vergote, Ignace, DePont Christensen, René, Graybill, Whitney, Mirza, Mansoor R, McCormick, Colleen, Lorusso, Domenica, Hoskins, Paul, Freyer, Gilles, Baumann, Klaus, Jardon, Kris, Redondo, Andrés, Moore, Richard G, Vulsteke, Christof, O’Cearbhaill, Roisin E, Lund, Bente, Backes, Floor, Barretina-Ginesta, Pilar, Haggerty, Ashley F, Rubio-Pérez, Maria J, Shahin, Mark S, Mangili, Giorgia, Bradley, William H, Bruchim, Ilan, Sun, Kaiming, Malinowska, Izabela A, Li, Yong, Gupta, Divya, Monk, Bradley J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Administration, Oral Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Breast cancer Cancer therapies Chemotherapy Combined Modality Therapy Double-Blind Method Double-blind studies Female Homologous recombination Humans Indazoles - adverse effects Indazoles - therapeutic use Maintenance Chemotherapy Medical diagnosis Middle Aged Mutation Nausea - chemically induced Neutropenia Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Ovarian Neoplasms - surgery Patients Piperidines - adverse effects Piperidines - therapeutic use Platinum Poly(ADP-ribose) polymerase Poly(ADP-ribose) Polymerase Inhibitors - adverse effects Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Population Progression-Free Survival Quality of Life Questionnaires Ribose Survival Survival Analysis Thrombocytopenia Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with newly diagnosed advanced ovarian cancer were randomly assigned to receive daily niraparib, a PARP inhibitor, or placebo as maintenance therapy after having had a response to platinum-based chemotherapy. Progression-free survival was significantly longer in the niraparib group than in the placebo group, with some increase in the frequency of myelosuppression and nausea.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1910962